To include your compound in the COVID-19 Resource Center, submit it here.

Prolia denosumab: Phase III data

Top-line data from the double-blind, double-dummy, international Phase III GIOP trial in 795 patients receiving glucocorticoid treatment showed that 60 mg subcutaneous Prolia every 6

Read the full 254 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE